Coloplast: VA Origin Certifications After Production Moved

Coloplast agreed to pay $14,547,347 to settle allegations of incorrect country-of-origin reporting and missed discounts in sales to the Department of Veterans Affairs. The medical product manufacturer self-reported incorrect countries of origin and products left on its contract after manufacturing moved to countries outside the contract’s permitted group. For someone who knows the factory, the product listing or the discount decisions, this case turns on a familiar question: did the government’s paperwork keep up with what changed inside the business?

The U.S. Attorney’s Office for the District of Columbia announced the settlement on December 12, 2022. A deputy chief in its Civil Division investigated the matter with assistance from the Department of Veterans Affairs inspector general’s audit and investigative personnel.

What Changed in Coloplast’s VA Product Records

The government’s origin allegations concerned both incorrect country reporting and products remaining on the contract after a manufacturing move. According to the settlement announcement, Coloplast disclosed that it had misapplied the Trade Agreements Act substantial-transformation standard. That analysis had led it to report incorrect countries of origin for several products it manufactured.

Coloplast also reported that some products stayed on the contract after their manufacturing locations switched to non-designated countries. The alleged problem reached the government’s product list as well as the origin information behind it.

We see the absurdity in the alleged mismatch: a manufacturer moves the work that makes a product while the government’s contract still carries it as eligible. The factory changes. The listing stays.

Why a Production Move Can Change Country of Origin

Coloplast’s country-of-origin problem began with how it assessed the manufacturing process under the Trade Agreements Act. Under the trade-agreement purchasing rules, substantial transformation concerns the creation of a new article with a distinct name, character or use. That makes the manufacturing process, and where it takes place, central to the origin analysis.

For a manufacturer with production in different places, the useful comparison is between the operations performed at each location and the origin represented for the finished product. A supplier address does not identify which operation made the product or transformed it into the article the government ordered.

The Buy American domestic-preference framework uses a different test involving U.S. manufacture and component costs for ordinary manufactured products.

This is why we connect an origin statement to a particular product and the manufacturing history behind it. Together, the manufacturing records and the listing history can show where the government’s description stopped matching the supplier’s account of the goods.

The VA Discounts Were a Separate Allegation

Coloplast also self-reported that it misapplied the Price Reductions Clause, failing to give the government discounts required by its contract. The government’s announcement said that failure led to overbilling for certain medical and pharmaceutical products. The settlement covered this pricing allegation alongside the origin allegations.

The pricing question follows the bargain: which discount should have reached the government, and which price did the government actually pay? Under the traditional Price Reductions Clause, the contract tied the government’s discount to a specified commercial customer or customer category. A better discount for that customer could require a lower government price.

That brings commercial sales records into a government purchasing case. The relevant discount may appear in actual transactions and concessions, beyond the company’s published price list. We connect those transactions to the comparison customer named in the contract, the contract terms in force, and the prices billed to the government.

For Coloplast, the government’s allegation was direct: required discounts had not been passed through, and the United States was overbilled. That belongs alongside the production story because a product’s eligibility and its price answer different questions about the same purchase.

The harm alleged here reaches the public purchasing budget. The Department of Veterans Affairs buys healthcare products on agreed terms, including the discounts. We see little comfort in a negotiated discount that disappears when it is time to bill.

What Similar Medical-Product Cases Show

In the Medtronic origin case, the government alleged that medical devices sold to the Department of Veterans Affairs came from countries outside the permitted group despite certifications stating otherwise.

The Novo Nordisk needle settlement concerned allegations that NovoFine needles supplied under government contracts originated in non-designated countries.

The government alleged that ICP Medical misrepresented the origin of medical goods and commercial discounts in sales to the Department of Veterans Affairs.

These government purchases of medical goods put origin and pricing decisions inside the health care supply chain. The records at issue concern what the supplier represented, what it delivered, and what it charged. The person who sees a production transfer, prepares a product listing or works with customer discounts may see the contradiction long before it appears in a government announcement.

What Are the Indicators of Government Procurement Fraud?

Government procurement fraud indicators in this case are origin statements that conflict with manufacturing history, products retained on a contract after their origin changes, and invoices that omit required discounts. Each points to a specific comparison we can examine with someone who knows the business.

On origin, we connect the product identifier, the represented country and the contract listing to the manufacturing operations before and after a move. We then connect that history to the goods supplied to the government. The timing matters because it connects a production change to the listing and purchases affected by it.

On pricing, we examine the commercial discount, the customer relationship the contract uses for comparison, and the government invoice for the relevant period. Those contract and billing records explain how an internal pricing decision could become an overcharge to the government. The origin and pricing accounts need their own evidence even when they concern the same product.

You may know the manufacturing side, the government-contract side or the pricing side. Our work is to connect what you know to the representation and the purchase it affected. That is where knowledge of the business gives a whistleblower case its substance.

How Much Money Can a Whistleblower Get From a Qui Tam Lawsuit?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. A procurement whistleblower reward follows the government’s recovery. We build the case behind that recovery around what you know about the products, representations and prices.

You Know What Changed Inside the Business

If you saw production move while a VA listing stayed in place, or discounts disappear before the government invoice, speak with our whistleblower experts. We build the case around your knowledge and bring in government procurement fraud whistleblower lawyers who understand medical-product origin and federal pricing promises. We stay beside you as your partners throughout the case, from the first conversation about what changed to the pursuit of a recovery.